These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24980947)

  • 1. Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells.
    Azarenko O; Smiyun G; Mah J; Wilson L; Jordan MA
    Mol Cancer Ther; 2014 Aug; 13(8):2092-103. PubMed ID: 24980947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
    Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
    Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance to cabazitaxel.
    Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
    Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical profile of cabazitaxel.
    Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
    Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    Sennoune SR; Nelius T; Jarvis C; Pruitt K; Kottapalli KR; Filleur S
    PLoS One; 2020; 15(6):e0234078. PubMed ID: 32484838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
    Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding modes of cabazitaxel with the different human β-tubulin isotypes: DFT and MD studies.
    Zhu L; Zhang C; Lü X; Song C; Wang C; Zhang M; Xie Y; Schaefer HF
    J Mol Model; 2020 May; 26(6):162. PubMed ID: 32474655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.
    Reynolds CP; Kang MH; Maris JM; Kolb EA; Gorlick R; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2015 Nov; 62(11):1897-905. PubMed ID: 26154614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
    de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
    Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microtubule dynamics, mitotic arrest, and apoptosis: drug-induced differential effects of betaIII-tubulin.
    Gan PP; McCarroll JA; Po'uha ST; Kamath K; Jordan MA; Kavallaris M
    Mol Cancer Ther; 2010 May; 9(5):1339-48. PubMed ID: 20442307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules.
    Kamath K; Okouneva T; Larson G; Panda D; Wilson L; Jordan MA
    Mol Cancer Ther; 2006 Sep; 5(9):2225-33. PubMed ID: 16985056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
    Wang R; Wang H; Wang Z
    J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
    Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
    Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
    Mang J; Merkle K; Heller M; Schüler J; Tolstov Y; Li J; Hohenfellner M; Duensing S
    Urol Oncol; 2017 Jan; 35(1):32.e9-32.e16. PubMed ID: 27692847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of microtubule dynamic instability and turnover in MCF7 breast cancer cells by sulforaphane.
    Azarenko O; Okouneva T; Singletary KW; Jordan MA; Wilson L
    Carcinogenesis; 2008 Dec; 29(12):2360-8. PubMed ID: 18952594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
    Mita AC; Figlin R; Mita MM
    Clin Cancer Res; 2012 Dec; 18(24):6574-9. PubMed ID: 23091116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.